ResearchA unique therapeutic approach to emesis and itch with a proanthocyanidin-rich genonutrientMark JS Miller1 , Brian K Reuter2 , John L Wallace3 and Keith A Sharkey4  1Center for Cardiovascular Sciences, Albany Medical College, Albany, New York, USA 2Department of Medicine, University of Virginia, Charlottesville, Virginia, USA 3Inflammation Research Network, Department of Pharmacology and Experimental Therapeutics, University of Calgary, Alberta, Canada 4Department of Physiology and Biophysics, University of Calgary, Calgary, Alberta, Canada author email corresponding author email
Journal of Translational Medicine 2008,
6:3doi:10.1186/1479-5876-6-3
|
|
| Published: |
18 January 2008 |
Abstract
Background
We examined the therapeutic potential of a proprietary Croton palanostigma extract (Zangrado®) in the management of emesis and itch.
Methods
Emesis was induced in ferrets with morphine-6-glucuronide (0.05 mg/kg sc) in the presence of Zangrado (3 mg/kg, ip) and the cannabinoid receptor 1 antagonist, AM 251 (5 mg/kg, ip). Topical Zangrado (1%) was assessed for anti-pruretic actions in the 5-HT-induced scratching model in rats and evaluated in capsaicin-induced gastric hyperemia as measured by laser doppler flow. In the ApcMinmouse model of precancerous adenomatosis polyposis, mice received Zangrado (100 μg/ml in drinking water) from the age of 6 – 16 weeks for effects on polyp number. In RAW 264.7 cells Zangrado was examined for effects on lipopolysaccharide-induced nitrite production.
Results
Zangrado was a highly effective anti-emetic, reducing morphine-induced vomiting and retching by 77%. These benefits were not associated with sedation or hypothermia and were not reversed by cannabinoid receptor antagonism. Itch responses were blocked in both the morphine and 5-HT models. Zangrado did not exacerbate the ApcMincondition rather health was improved. Capsaicin-induced hyperemia was blocked by Zangrado, which also attenuated the production of nitric oxide by activated macrophages.
Conclusion
Zangrado is an effective anti-emetic and anti-itch therapy that is devoid of common side-effects, cannabinoid-independent and broadly suppresses sensory afferent nerve activation. This complementary medicine represents a promising new approach to the management of nausea, itch and irritable bowel syndrome. |